Ophthalmology and Therapy (May 2024)

Burden of Disease Study of Patients with Neovascular Age-Related Macular Degeneration in Spain

  • Maximino J. Abraldes,
  • Pilar Calvo,
  • María Gámez Lechuga,
  • María Merino,
  • Teresa Martín Lorenzo,
  • Paulina Maravilla-Herrera,
  • Beatriz Gil Jiménez,
  • José M. Ruiz-Moreno

DOI
https://doi.org/10.1007/s40123-024-00960-9
Journal volume & issue
Vol. 13, no. 7
pp. 1925 – 1935

Abstract

Read online

Abstract Introduction Neovascular age-related macular degeneration (nAMD) is a progressive retinal disease that causes severe and irreversible vision loss. The disease can therefore have a significant impact on the life of patients’ and their families. The aim of this study was to evaluate the socio-economic burden of nAMD in Spain. Methods The annual cost per patient with nAMD was estimated for the first, second, and third year (or beyond) of treatment since diagnosis. Several cost categories were considered including direct healthcare costs (DHC), direct non-healthcare costs (DNHC), labor productivity losses (LPL), and intangible costs (IC) related to loss of quality of life. The average annual cost per patient was estimated by assigning a unit price or financial proxy to the resources consumed per patient. Reference year of costs was 2021. Results The mean annual cost of nAMD was estimated at €17,265, €15,403, and €14,465 per patient in the first, second, and third year of treatment after diagnosis. There was an additional one-off cost of €744 associated with the diagnosis of nAMD. DHC accounted for most of the total annual cost per patient independent of the year of treatment since diagnosis (48% in year 1; 42% in year 2; 39% in year 3). Similarly, DNHC had an important contribution to the total costs (32% in year 1; 35% in year 2; 37% in year 3), followed by IC (20% in year 1; 23% in year 2; 24% in year 3), while the contribution of patients’ LPL was minimal. Conclusion This study estimated a high economic burden associated with nAMD for patients and their families, the healthcare system, and society at large. There is a need to improve the management of these patients to reduce the impact of nAMD disease progression.

Keywords